linjc16/ctgov huggingface dataset:
The Impact of COVID-19 Pandemic on Cancer Care

Study Overview
=================
Brief Summary
-----------------
The situation of COVID-19 pandemic creates many challenges for cancer patients and caregivers. Some modifications in cancer management have been evolved from cancer societies and organizations to support oncology professionals as much as possible to deliver optimal care to their cancer patients in such exceptional circumstances, and to protect patients from infection with COVID-19 as much as possible.

Detailed Description
-----------------
In oncology practice during this pandemic, many cancer patients still feeling uncertainty about their cancer management and treatment outcome . The study is aiming to better understand the impact of the COVID-19 pandemic on cancer care from patients' and survivors' perspective.

Official Title
-----------------
Impact of COVID-19 Pandemic on Cancer Care Provision: a Cross-sectional Study of Egyptian Patients' Perspectives and Concerns

Conditions
-----------------
Cancer

Intervention / Treatment
-----------------
* Other: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cancer patients or survivors in Egypt. Exclusion Criteria: No exclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: survey|online survey|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patients' and survivors' perspective of their cancer care during COVID-19 pandemic | measured by online survey to understand the impact of COVID-19 pandemic on cancer care | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer Care, COVID-19
Registry Study of ID & IDA in Korean Patients With Heart Failure

Study Overview
=================
Brief Summary
-----------------
The prevalence of Iron Deficiency and Iron Deficiency Anemia in Korean HF patient

Detailed Description
-----------------
Epidemiological study to assess The prevalence of ID (Iron Deficiency) & IDA (Iron Deficiency Anemia) in Korean patients with heart failure

Official Title
-----------------
The Prevalence of ID (Iron Deficiency) & IDA (Iron Deficiency Anemia) in Korean Patients With Heart Failure

Conditions
-----------------
Iron Deficiency Anemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: more than 19 years old Informed Consent Form Hear Failure criteria as belows Heart Failure Sign(more than 1 Sx such as fatigue, dyspnea, ankle swelling) Heart Failure Symptom(more than 1 among Jugular venous pressure (JVP) elevation, pulmonary crackle, peripheral edema) ③ Lung congestion or edema at chest X-ray ④ Objective findings of structural or functional cardiac abnormality(more than abnormality level of BNP or NT-proBNP, abnormality of echocardiography ) Exclusion Criteria: Not applicable
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Prevalence of Iron Deficiency | serum ferritin < 100 ㎍/L or serum ferritin 100-299 ㎍/L and TSAT* < 20% | 1 day | 
| The Prevalence of Iron Deficiency Anemia | include Iron Deficiency criteria & Male: Hb < 13 g/dL, Female Hb < 12 g/dL | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Current Anemia treatment | Number of Participants take Anemia Medication | 1 day |
Angiogenesis in Early Breast Cancer for Prognosis Prediction

Study Overview
=================
Brief Summary
-----------------
This study will investigate the association of angiogenesis in breast cancer measured by magnetic resonance imaging and biomarkers with long-term prognosis of patients.

Official Title
-----------------
Angiogenesis in Early Breast Cancer for Prognosis Prediction

Conditions
-----------------
Breast Lesions

Intervention / Treatment
-----------------
* Procedure: magnetic resonance imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with a breast mass highly suspicious for malignancy from clinical, mammographic or sonographic examination. The study has been explained to the patient when she is scheduled for surgery. Healthy normal volunteers for imaging protocol optimization. Exclusion Criteria: Pregnancy Patients with implanted surgical clips (hemostatic clips) or other ferromagnetic material, Patients engaged in occupations or activities which may cause accidental lodging of ferromagnetic materials, or who may have imbedded metal fragments from military activities, Patients with metallic implants, because they may cause artifacts in diagnostic images due to magnetic field distortion, Patients with implanted prosthetic heart valves, Patients with pacemakers, neuro-stimulation devices, A breast mass with features of benign tumor The patients unwilling to participate in the study or fail to sign the consent form

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate whether breast cancer with a higher angiogenesis activity is associated with a unfavorable outcome. |  | 5 years from completion of enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To investigate whether angiogenesis of breast cancer is associated wit lymph node status |  | at completion of enrollment |
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.

Official Title
-----------------
An Open Label, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolism and Pharmacokinetics Following Oral Administration of [14C]AZD2066 to Healthy Male Subjects

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: AZD2066


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Provision of signed informed consent Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG. Exclusion Criteria: History of somatic disease/condition, which may interfere with the objectives of the study. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder. Healthy volunteers who have been exposed to radiation levels above background (eg, through X-ray examinations).

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: AZD2066|1 dose oral solution|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Excretion (rate and extent) of radioactivity in urine and faeces following oral administration of [14C]AZD2066 |  | Until >90% of predicted total radioactivity has been recovered | 
| Pharmacokinetics of total radioactivity in plasma and unchanged AZD2066 in plasma |  | Sampling at defined timepoints during residential period from pre-dose until 168h post-dose. | 
| Metabolite profile in plasma and excreta |  | Sampling at defined timepoints during residential period from pre-dose until 48h post-dose. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AZD2066 metabolites in plasma+excreta if feasable |  | Sampling at defined timepoints during residential period from pre-dose until 48h post-dose. | 
| Safety and tolerability of AZD2066 by assessment of vital signs, laboratory variables, ECG and adverse events |  | Assessments taken at visit 1 (enrolment), defined time points pre dose and post dose during visit 2 (residential period) and follow up visit 3. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Mass balance, AZD2066, Pain, Pain conditions
The Influence of Bariatric Surgery on Patients With Obstructive Sleep Apnea (OSA)

Study Overview
=================
Brief Summary
-----------------
Obesity is a very important risk-factor in obstructive sleep apnea (OSA) and other sleep breathing disorders in patients with extreme BMI. Candidates for bariatric surgery have a high OSA prevalence, ranging from 60-83%. The characteristics of patients with sleep apnea that were evaluated for bariatric surgery and had a full overnight polysomnography (PSG) screening for OSA were described and it was found that a very high prevalence (77.2%) for OSA in all subjects evaluated, regardless of pre-operative risk for OSA. A post-bariatric surgery PSG was not a part of this study. The investigators would like to demonstrate the impact of bariatric surgery on OSA as a function of time.

Official Title
-----------------
The Influence of Bariatric Surgery on Patients With Obstructive Sleep Apnea (OSA)

Conditions
-----------------
Overweight, Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All candidates for bariatric surgery over 18 yrs of age Exclusion Criteria: Patients that underwent any OSA surgery in the past Patient had any bariatric surgery in the past Patients with COPD Patients with CHD Patients who have / had cancer that received chemotherapy or radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Bariatric surgery patients<br>Candidates for bariatric surgery. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in RDI after bariatric surgery | Improvement will measured by polysonography | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bariatric surgery, sleep apnea, overweight
Study of Nicotine for the Prevention of PONV

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether nicotine is effective in the prevention of nausea and vomiting in non-smokers undergoing surgery

Official Title
-----------------
The Role of Transcutaneous Nicotine in the Prevention of Postoperative Nausea and Vomiting in Non-smokers

Conditions
-----------------
Postoperative Nausea and Vomiting

Intervention / Treatment
-----------------
* Drug: Nicotine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults (18-80 years) ASA I-II, non-smokers (or ex-smokers who have not been smoking for more than 2 years) Undergoing elective surgery (ENT, abdominal, urological, gynaecological); and Consenting to take part in the study will be included. Exclusion Criteria: Smokers (cigarette, pipe, cigar) Patients undergoing nicotine replacement therapy Prolonged postoperative intubation Postoperative nasogastric tube

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nicotine patch<br>Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10) | Drug: Nicotine<br>* Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)<br>|
| Placebo Comparator: Placebo patch<br>Placebo patch 10 cm2 | Drug: Nicotine<br>* Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevention of PONV |  | 48 hours postoperatively | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse effects that may be related to the nicotine patch, for instance, local skin reaction. |  | 48 hours postoperatively | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
nausea, vomiting, retching, emesis, surgery, anesthesia
Outdoor Allergen Exposure, Sensitivity, and Acute Asthma

Study Overview
=================
Brief Summary
-----------------
To examine the role of outdoor pollen grains and fungal spores in the exacerbation of asthma and to produce forecasting models to predict days of high concentration.

Detailed Description
-----------------
Asthma is a growing problem, and outdoor allergens play a role in exacerbation of many cases. A clearer understanding of this role and its magnitude, and a means of controlling the effects of outdoor allergen exposures is needed. We propose Poisson time-series and conditional panel studies to test these hypotheses: 1) The incidence of acute asthma attacks, as measured by urgent care inhalation treatments and hospitalizations for asthma, has a dose-dependent relationship with exposure to specific outdoor allergens; 2) Specific sensitization to outdoor allergens is a risk factor for having an acute attack; and 3) Exposure conditions that lead to acute asthma attacks can be forecast, creating an opportunity to reduce asthma morbidity and mortality ny targeting pretreatment and/or exposure controls.

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Must be a member of the Fallon HMO and be treated for acute asthma exacerbation.

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Allergens
Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if implitapide is effective in lowering triglyceride (TG) levels in patients with Fredrickson Type I or V hypertriglyceridemia where the maximum tolerable medication and diet were not sufficient.

Official Title
-----------------
An Open-Label, Dose-Escalating Efficacy and Safety Study of Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy

Conditions
-----------------
Hypertriglyceridemia

Intervention / Treatment
-----------------
* Drug: implitapide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In order to participate in this study, patients must meet all of the following inclusion criteria: be between 8 and 70 years old with diagnosis of Fredrickson Type I or V HTG be stable on current maximum tolerated triglyceride lowering therapy have a fasting TG level of at least 880 mg/dL (10 mmol/L) be male or nonpregnant, nonbreastfeeding female. The women in the study must be surgically sterile, postmenopausal or must practice an effective method of birth control must be able to give informed consent or if under the age of 18, parents or legal guardians must give their informed consent meet body weight requirements Exclusion Criteria: Recent heart attack, coronary artery intervention, coronary bypass surgery, or stroke. Patients with class 3 or 4 heart failure Uncontrolled hypothyroidism or other uncontrolled endocrine disease Known, clinically significant eye abnormalities, such as cataracts History of hepatic disease or AST or ALT levels greater than 1.5 x ULN at Visit 1 Alkaline phosphatase greater than 2 times ULN Serum creatinine greater than 2.0 mg/dL Liver cirrhosis and severe liver steatosis Clinically significant infection, malignancy, or psychosis Use of oral anticoagulants or digoxin unless the dose is stable and is regularly monitored Participation in any other investigational study within the last 30 days Breastfeeding or pregnant Current drug or alcohol abuse Serious or unstable medical conditions that would compromise the patient's safety or successful participation in the study Unwillingness to comply with study procedures or unwillingness to cooperate fully

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: implitapide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HTG, Hypertriglyceridemia, Fredrickson Type I, Hypertriglyceridemia, Fredrickson Type V
Non-invasive Assessment of Arterial Blood Pressure and Functional Hemodynamic Parameters

Study Overview
=================
Brief Summary
-----------------
Cardiac output can be monitored using different invasive devices. Nexfin HD is a new, noninvasive device that uses model flow technology to measure stroke volume and thus computes cardiac output (CO). To evaluate this new device the investigators compared esophageal doppler CO to Nexfin HD CO in patients scheduled for elective abdominal surgery.

Official Title
-----------------
An Evaluation of a New, Non-invasive Monitoring Device in Major Abdominal Surgery Patients

Conditions
-----------------
Surgical Procedure, Unspecified

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 and < 80 years old Written informed consent obtained Exclusion Criteria: Renal failure Heart failure (EF < 25%) Peripheral artery occlusion disease M. Raynaud Rhythms other than sinus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stroke volume, cardiac output, validation
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

Study Overview
=================
Brief Summary
-----------------
This is a retrospective study to assess the clinical efficacy and safety of trientine in Wilson's disease patients

Detailed Description
-----------------
In this retrospective study, the investigators will collect and analyze data from reviewing medical history files of larger and long-term follow-up cohorts with Wilson's disease in Taiwan to assess the efficacy and safety of Trientine in Taiwanese Wilson's Disease patients.

Official Title
-----------------
A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients

Conditions
-----------------
Trientine Treatment for Wilson's Disease

Intervention / Treatment
-----------------
* Drug: Trientine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Wilson's disease. Male or female patients, aged 3 years to 75 years Exclusion Criteria: Patients with comorbidity which is not related to Wilson's disease.

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Trientine|Trientine is a chelating agent for removing the copper from the body|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The improvement in liver function | To measure the AST (aspartate aminotransferase), ALT (alanine transaminase), GGT (gamma-glutamyl transpeptidase), Albumin, and Bilirubin level, and compare to the baseline | Up to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The improvement in urine copper excretion | To measure 24-hour urine copper levels during the study period | Up to 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
trientine, Wilson's disease